Aaron Cowen’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,768,712
| Closed | -$96M | – | 100 |
|
|
2026
Q1 | $96M | Hold |
4,768,712
| – | – | 2.45% | 16 |
|
|
2025
Q4 | $77M | Hold |
4,768,712
| – | – | 1.58% | 27 |
|
|
2025
Q3 | $58.1M | Sell |
4,768,712
-186,288
| -4% | -$2.57M | 1.49% | 24 |
|
|
2025
Q2 | $56M | Buy |
4,955,000
+41,988
| +0.9% | +$513K | 1.69% | 21 |
|
|
2025
Q1 | $56.7M | Hold |
4,913,012
| – | – | 2.1% | 14 |
|
|
2024
Q4 | $41.6M | Buy |
4,913,012
+701,007
| +17% | +$7.26M | 1.42% | 24 |
|
|
2024
Q3 | $48.8M | Buy |
4,212,005
+20,000
| +0.5% | +$252K | 1.56% | 24 |
|
|
2024
Q2 | $49.4M | Hold |
4,192,005
| – | – | 1.81% | 17 |
|
|
2024
Q1 | $49.7M | Buy |
4,192,005
+1,508,000
| +56% | +$20.1M | 1.85% | 17 |
|
|
2023
Q4 | $32.9M | Buy |
2,684,005
+263,154
| +11% | +$2.39M | 1.49% | 25 |
|
|
2023
Q3 | $23.3M | Buy |
2,420,851
+386,345
| +19% | +$3.95M | 1.26% | 26 |
|
|
2023
Q2 | $18.3M | Buy |
2,034,506
+51,327
| +3% | +$473K | 0.98% | 37 |
|
|
2023
Q1 | $15.6M | Buy |
1,983,179
+910,877
| +85% | +$6.8M | 0.66% | 44 |
|
|
2022
Q4 | $7.25M | Sell |
1,072,302
-634,798
| -37% | -$3.4M | 0.3% | 53 |
|
|
2022
Q3 | $24.8M | Sell |
1,707,100
-221,100
| -11% | -$3.09M | 1.03% | 40 |
|
|
2022
Q2 | $19M | Buy |
1,928,200
+181,900
| +10% | +$2.01M | 0.72% | 46 |
|
|
2022
Q1 | $25.7M | Hold |
1,746,300
| – | – | 0.79% | 41 |
|
|
2021
Q4 | $23.1M | Buy |
1,746,300
+203,016
| +13% | +$3.23M | 0.45% | 47 |
|
|
2021
Q3 | $26.9M | Buy |
1,543,284
+352,183
| +30% | +$7.14M | 0.45% | 45 |
|
|
2021
Q2 | $28.5M | Buy |
1,191,101
+231,209
| +24% | +$6.05M | 0.43% | 52 |
|
|
2021
Q1 | $24.7M | Buy |
959,892
+650,992
| +211% | +$17.1M | 0.36% | 54 |
|
|
2020
Q4 | $5.87M | Hold |
308,900
| – | – | 0.08% | 72 |
|
|
2020
Q3 | $3.89M | Buy |
308,900
+61,900
| +25% | +$774K | 0.07% | 68 |
|
|
2020
Q2 | $2.99M | Buy |
247,000
+132,800
| +116% | +$1.41M | 0.06% | 63 |
|
|
2020
Q1 | $874K | Buy |
+114,200
| New | +$1.54M | 0.02% | 53 |
|
Other funds holding KALV
Aaron Cowen's KALV Position: Q2 2026 in Review
Aaron Cowen sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 4,768,712 shares — an estimated $96M sold.
Aaron Cowen first reported a position in KALV in Q1 2020 and held it in 25 quarters. The position peaked at $96M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Aaron Cowen reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Aaron Cowen sold 4,768,712 KalVista Pharmaceuticals shares in Q2 2026, an estimated $96M.
- Aaron Cowen first reported a position in KalVista Pharmaceuticals in Q1 2020 and held it in 25 quarters.
- Aaron Cowen's KalVista Pharmaceuticals position peaked at $96M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.